Helping melanoma patients decide whether to choose adjuvant high-dose interferon-alpha2b. Review uri icon

Overview

abstract

  • High-dose interferon-alpha2b is a U.S. Food and Drug Administration-approved adjuvant treatment for stage III melanoma, and yet, because of its limited efficacy and well-known toxicity, it is not universally accepted by patients and oncologists. In this paper, we evaluate the benefits and risks of adjuvant high-dose interferon-alpha2b and try to provide a framework to help oncologists guide patients trying to decide whether to undergo adjuvant high-dose interferon therapy.

publication date

  • October 1, 2005

Research

keywords

  • Interferon-alpha
  • Melanoma

Identity

Scopus Document Identifier

  • 27644510419

Digital Object Identifier (DOI)

  • 10.1634/theoncologist.10-9-739

PubMed ID

  • 16249355

Additional Document Info

volume

  • 10

issue

  • 9